Redeye provides an update following SenzaGen’s Q1 2025 report. The quarterly figures came in a bit below our expectations; however, we argue that the long-term outlook and our investment case are intact. Based on the report, we make some downward changes to our sales estimates, rendering an updated fair value range.
LÄS MER
